Next Generation Sequencing Market Size, Share, Growth, and Industry Analysis, By Type (Ion semiconductor sequencing, Sequencing by the synthesis (SBS), Nanopore sequencing, Single-molecule real-time (SMRT) sequencing), By Application (Biotechnology and Pharmaceutical Companies, Research Centres, Hospitals & Clinics, Others), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

NEXT GENERATION SEQUENCING MARKET OVERVIEW

The global Next Generation Sequencing Market size is estimated at USD 24.68 billion in 2026 and is projected to reach USD 119.78 billion by 2035, growing at a CAGR of 19.19% from 2026 to 2035.

The next-generation sequencing market is advancing through high-throughput sequencing, clinical genomics, precision oncology, population genomics, rare-disease analysis, and multiomics research. Sequencing by synthesis remains the dominant technology, representing approximately 62% of technology adoption, supported by high accuracy, scalable throughput, validated workflows, and a large installed instrument base. Long-read nanopore and single-molecule technologies are expanding for structural variant detection, genome assembly, transcriptomics, and complex genomic regions. Modern high-throughput platforms can process billions of sequencing reads per run, while integrated bioinformatics increasingly converts raw genomic data into clinically interpretable variants. These capabilities are strengthening next-generation sequencing adoption across pharmaceutical, research, hospital, and diagnostic environments.

The United States represents the largest national center for next-generation sequencing adoption, supported by advanced genomic laboratories, academic medical centers, biotechnology companies, pharmaceutical research, and precision medicine programs. Sequencing is increasingly integrated into oncology profiling, inherited disease testing, reproductive genetics, infectious disease surveillance, and population genomics. The country also has a strong concentration of sequencing platform manufacturers, bioinformatics developers, clinical laboratories, and genomic research organizations. Federal research programs, university sequencing centers, private genomic initiatives, companion diagnostic development, and regulatory acceptance of next-generation sequencing tests continue to expand clinical utilization. Automated sequencing and cloud-based genomic analysis are additionally improving laboratory scalability.

KEY FINDINGS

LATEST TRENDS

The next-generation sequencing market is shifting toward higher throughput, improved sequencing accuracy, automated sample preparation, multiomics, long-read sequencing, artificial intelligence-assisted interpretation, and decentralized genomic testing. High-throughput platforms are increasingly optimized for whole-genome sequencing, single-cell analysis, transcriptomics, proteomics-linked applications, and large population studies. Sequencing system performance continues to improve substantially. NovaSeq X technology enhancements announced in 2026 target output of up to 35 billion reads and sequencing quality reaching Q70, demonstrating the industry's movement toward greater accuracy and laboratory productivity. The same platform roadmap includes faster processing and greater batching flexibility for genomic laboratories.

Long-read sequencing is another major next-generation sequencing market trend. Nanopore sequencing and single-molecule real-time sequencing enable researchers to examine structural variants, repetitive genomic regions, haplotypes, transcript isoforms, and genome assemblies that can be difficult to resolve using conventional short reads. Clinical sequencing is also expanding. Oncology laboratories increasingly use targeted next-generation sequencing for simultaneous assessment of numerous genomic alterations. Bioinformatics automation is becoming equally important as laboratories manage larger datasets and require faster variant calling, interpretation, reporting, storage, and integration with clinical systems.

MARKET DYNAMICS

Driver

Expanding adoption of precision medicine and genomic profiling.

Precision medicine is a major driver of next generation sequencing market growth because genomic information increasingly supports disease classification, biomarker identification, targeted therapy selection, and drug development. Oncology represents a particularly important adoption area because sequencing allows laboratories to investigate numerous clinically relevant genes within a single workflow. Regulatory acceptance also demonstrates increasing clinical maturity. A currently authorized comprehensive oncology test can assess variants across 517 genes while additionally reporting tumor mutational burden and microsatellite instability status. Pharmaceutical companies are integrating sequencing into biomarker discovery, clinical trial enrollment, companion diagnostics, and treatment-response research. Population genomics programs further increase sequencing volumes and create demand for high-throughput instruments, consumables, data infrastructure, and bioinformatics.

Driver Impact Analysis*

Restraint

Complex genomic data management and interpretation requirements.

The growing volume and complexity of sequencing data remain significant restraints for next generation sequencing laboratories. High-throughput instruments can generate billions of reads, requiring substantial computational capacity, secure storage, validated analytical pipelines, trained bioinformaticians, and standardized interpretation procedures. Laboratories entering clinical sequencing must additionally address quality assurance, regulatory requirements, sample tracking, variant classification, cybersecurity, and patient data protection. Long-read and multiomic applications further increase computational complexity because datasets can contain structural variants, transcript information, methylation signals, and other biological features. Smaller hospitals and research centers can therefore face infrastructure and expertise barriers despite improvements in sequencing automation. Cloud computing, artificial intelligence, standardized pipelines, and integrated analysis

Restraint Impact Analysis*

Expansion of population genomics, clinical diagnostics, and multiomics.

Opportunity

Population-scale genomic programs create substantial opportunities for the next generation sequencing market because they require sequencing platforms, sample preparation systems, consumables, informatics, cloud storage, and analytical software. The United States All of Us research dataset incorporated nearly 250,000 whole-genome sequences and enabled identification of more than 275 million previously unreported genetic variants, illustrating the research potential of large genomic datasets.

Additional opportunities are emerging in single-cell sequencing, spatial biology, liquid biopsy, rare-disease testing, pharmacogenomics, infectious disease surveillance, agricultural genomics, and newborn sequencing. Combining genomic information with transcriptomic, epigenomic, and proteomic measurements can create more detailed biological profiles and increase sequencing utilization across biotechnology, pharmaceutical research, hospitals, academic laboratories, and translational medicine programs.

Maintaining sequencing accuracy, standardization, and clinical interpretation at increasing scale.

Challenge

The next generation sequencing market faces the challenge of converting rapidly increasing sequencing capacity into reproducible and clinically meaningful information. Laboratories must control sample quality, library preparation, sequencing chemistry, contamination, coverage uniformity, variant calling, annotation, and reporting. Different sequencing technologies also exhibit different read lengths, throughput levels, error characteristics, and workflow requirements.

Clinical adoption requires analytical validation and consistent interpretation, particularly when sequencing identifies variants with uncertain clinical significance. Genomic laboratories must simultaneously manage data security and patient privacy. High-throughput sequencing further increases storage and computational requirements. Continued development of quality standards, reference materials, automated bioinformatics, artificial intelligence-assisted interpretation, standardized reporting frameworks, and interoperable clinical systems remains important for addressing these challenges.

•   
•   
  

  Download Free Sample to learn more about this report

    

NEXT GENERATION SEQUENCING MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into Ion semiconductor sequencing, Sequencing by the synthesis (SBS), Nanopore sequencing, and Single-molecule real-time (SMRT) sequencing.

• Ion semiconductor sequencing: Ion semiconductor sequencing accounts for approximately 17% of the defined next generation sequencing technology segmentation. The technology detects hydrogen ions released during nucleotide incorporation rather than relying on optical fluorescence detection. This architecture supports compact instrumentation and comparatively rapid sequencing workflows. Ion semiconductor systems are particularly relevant for targeted sequencing, oncology panels, microbial sequencing, inherited disease research, and clinical laboratory workflows requiring manageable throughput. Integrated platforms can automate substantial portions of sample-to-result processing.

• Sequencing by synthesis (SBS): Sequencing by synthesis holds approximately 62% of the defined technology market, making it the leading next-generation sequencing method. SBS identifies individual bases during incorporation into growing DNA strands and enables massively parallel analysis of large numbers of DNA fragments. Its leadership reflects strong sequencing accuracy, scalable throughput, extensive validated applications, established bioinformatics pipelines, and broad adoption across academic, pharmaceutical, biotechnology, and clinical laboratories.

• Nanopore sequencing: Nanopore sequencing represents approximately 13% of the defined next-generation sequencing technology segmentation. The technology measures changes in electrical current as nucleic acid molecules pass through nanoscale pores, allowing direct analysis of individual DNA or RNA molecules. Nanopore sequencing is differentiated by long reads, real-time data generation, portable instrument formats, and potential direct detection of molecular modifications. These capabilities make the technology useful for structural variant analysis, microbial genomics, genome assembly, transcript isoform characterization, infectious disease surveillance, and field-based sequencing.

• Single-molecule real-time (SMRT) sequencing: Single-molecule real-time sequencing holds approximately 8% of the defined technology segmentation. SMRT sequencing monitors DNA synthesis at the individual molecule level and produces long, highly accurate consensus reads suitable for complex genomic analysis. The technology is valuable for structural variant identification, de novo genome assembly, haplotype phasing, repeat expansion analysis, full-length transcript sequencing, microbial genomics, and difficult genomic regions. Long-read information can resolve genetic structures that short-read approaches may fragment or map ambiguously.

By Application

Based on Application, the global market can be categorized into Biotechnology and Pharmaceutical Companies, Research Centres, Hospitals & Clinics, and Others.

• Biotechnology and Pharmaceutical Companies: Biotechnology and pharmaceutical companies account for approximately 42% of the defined next-generation sequencing application segmentation. These organizations use sequencing throughout drug discovery, biomarker identification, target validation, translational research, clinical trial development, companion diagnostic programs, pharmacogenomics, cell and gene therapy development, and treatment-response analysis. Next-generation sequencing allows pharmaceutical researchers to characterize genomic alterations and stratify clinical trial participants using molecular biomarkers. Single-cell sequencing and transcriptomics are also increasingly applied to understand cellular heterogeneity and therapeutic mechanisms.

• Research Centres: Research centres represent approximately 29% of the defined application market. Universities, genomic institutes, government laboratories, and specialized research organizations use next-generation sequencing for human genetics, population genomics, evolutionary biology, microbiology, agriculture, transcriptomics, epigenomics, and disease research. Large genomic datasets demonstrate the scale of modern research applications. One major United States research resource contains nearly 250,000 whole-genome sequences and has supported discovery of more than 275 million previously unreported genetic variants.

• Hospitals & Clinics: Hospitals and clinics hold approximately 22% of the defined next-generation sequencing application segmentation. Clinical sequencing is increasingly used in oncology, inherited disease assessment, reproductive genetics, infectious disease analysis, and selected rare-disease workflows. Oncology is particularly important because targeted NGS panels can evaluate multiple actionable genomic alterations from limited patient material. Regulatory approvals are supporting greater integration of sequencing into treatment selection. In 2026, expanded indications for NGS companion diagnostic tests included additional genomic biomarkers associated with targeted therapies.

• Others: Others account for approximately 7% of the defined next-generation sequencing application market. This segment includes contract research organizations, forensic laboratories, agricultural genomics providers, veterinary laboratories, public health laboratories, environmental sequencing organizations, and specialized testing services. Applications include pathogen surveillance, food safety, plant breeding, animal genetics, metagenomics, biodiversity research, environmental monitoring, and forensic identification. Portable sequencing technologies are widening opportunities for genomic analysis outside centralized laboratories.

•   
•   
  Download Free Sample to learn more about this report

    

NEXT GENERATION SEQUENCING MARKET REGIONAL INSIGHTS

• North America

North America accounts for about 45% of the normalized next-generation sequencing market, maintaining the largest regional share. The United States drives regional adoption through extensive biotechnology activity, pharmaceutical research, clinical genomics, academic sequencing facilities, precision oncology, and population-scale genomics. Public genomic research has created datasets containing nearly 250,000 whole-genome sequences, demonstrating the scale of sequencing infrastructure available to researchers.

The region also hosts major sequencing technology companies, bioinformatics providers, clinical laboratories, and precision medicine organizations. Illumina reported an active installed base of about 21,000 sequencing systems globally, with a strong corporate and operational footprint in the United States.

• Europe

Europe represents approximately 24% of the normalized global next-generation sequencing market. The region benefits from established university research systems, national genomic medicine programs, public healthcare infrastructure, biotechnology clusters, pharmaceutical research, and collaborative genomic networks. The United Kingdom, Germany, France, Switzerland, the Netherlands, and other European countries maintain significant sequencing and bioinformatics capabilities. European genomic programs increasingly connect sequencing with rare-disease diagnosis, cancer genomics, pathogen surveillance, population research, and personalized healthcare. Oxford Nanopore Technologies provides the region with an important position in long-read sequencing innovation, while QIAGEN, Lexogen, and other genomics companies contribute sample preparation, analysis, assay, and workflow technologies.

• Asia Pacific

Asia Pacific accounts for approximately 22% of the normalized next-generation sequencing market and represents a major expansion center for genomic research and sequencing capacity. China, Japan, South Korea, India, Singapore, and Australia have developed significant capabilities in genomics, biotechnology, precision medicine, and clinical research.

China has extensive sequencing infrastructure supported by BGI Group and associated genomics operations, while Japan maintains advanced pharmaceutical and life sciences research. South Korea supports sequencing services through companies including Macrogen, and India continues expanding genomics laboratories and bioinformatics capabilities.

• Middle East & Africa

Middle East & Africa accounts for approximately 4% of the normalized global next-generation sequencing market. Sequencing adoption is concentrated in major medical centers, universities, public health laboratories, genetic testing facilities, and national genomic initiatives. Countries in the Gulf region are investing in precision medicine and population genomics to improve understanding of inherited disorders and population-specific genetic variation.

Genomic sequencing is particularly relevant because genetically diverse populations and consanguinity patterns can create valuable opportunities for rare-disease and inherited-condition research. African sequencing capacity is expanding through infectious disease genomics, pathogen surveillance, population genetics, and research partnerships.

• Rest of the World

Rest of the World represents approximately 5% of the normalized next-generation sequencing market. This category includes genomic activity across Latin America and other markets outside the primary regional classifications. Brazil, Mexico, Argentina, and other countries are increasing sequencing utilization in biomedical research, infectious disease surveillance, agricultural genomics, oncology, and inherited disease studies.

Public health sequencing gained greater strategic importance through pathogen genomic surveillance, while universities increasingly incorporate NGS into molecular biology and genetics programs. Agricultural sequencing represents another opportunity because the region has significant crop, livestock, and biodiversity resources.

KEY INDUSTRY PLAYERS

Competition in the next-generation sequencing market centers on sequencing accuracy, throughput, instrument accessibility, long-read capability, automation, clinical validation, consumable ecosystems, and bioinformatics integration. Illumina maintains a major position through sequencing by synthesis platforms and a global installed base of approximately 21,000 active instruments. Thermo Fisher Scientific competes through Ion Torrent sequencing, integrated clinical workflows, oncology assays, and automated sequencing systems.

Oxford Nanopore Technologies focuses on real-time long-read sequencing, while BGI Group contributes high-throughput genomic capabilities. QIAGEN, Agilent Technologies, Danaher-associated businesses, Takara Bio, Tecan, Zymo Research, DNAnexus, DNASTAR, and other companies strengthen sample preparation, automation, informatics, and genomic analysis.

LIST OF TOP NEXT GENERATION SEQUENCING COMPANIES

• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• BGI Group
• PerkinElmer Inc.
• Macrogen
• Hamilton Company
• Lucigen
• Intrexon Bioinformatics GmbH
• Partek Incorporated
• DNASTAR, Inc.
• DNAnexus
• SciGenom Labs Pvt. Ltd.
• GENEWIZ
• Takara Bio Inc.
• Becton Dickinson and Company
• Danaher
• Lexogen GmbH
• Tecan Trading AG
• Zymo Research
• Oxford Nanopore Technologies
• Agilent Technologies, Inc.
• QIAGEN

Market Leadership Matrix – Next Generation Sequencing Market

List of Top 2 Companies with Highest Market Share

• Illumina: Leads next-generation sequencing through its extensive SBS platform ecosystem and approximately 21,000 active installed sequencing systems globally.
• Thermo Fisher Scientific: Maintains a major position through Ion Torrent technology, automated workflows, clinical assays, and integrated genomic analysis capabilities.

LEADER INSIGHTS

• Illumina, Inc.: Jacob Thaysen, Chief Executive Officer, indicated that clinical sequencing remains an important growth engine as customers expand sequencing-intensive applications, while NovaSeq X adoption and broader multiomics capabilities create additional opportunities across clinical research and biopharma markets. (Published: July 30, 2026 | Source: https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=29026)

• Thermo Fisher Scientific, Inc.: Marc N. Casper, Chairman, President and Chief Executive Officer, emphasized strengthening customer activity across company end markets, with expanding scientific capabilities and technology investments supporting continued adoption and long-term opportunities across life sciences and genomic research. (Published: July 23, 2026 | Source: https://ir.thermofisher.com/investors/news-events/news/news-details/2026/Thermo-Fisher-Scientific-Reports-Second-Quarter-2026-Results/)

• Oxford Nanopore Technologies: Francis Van Parys, Chief Executive Officer, highlighted opportunities across research, clinical and biopharma sequencing as Oxford Nanopore expands its technology platform, strengthens customer focus, and advances broader commercial adoption of nanopore sequencing worldwide. (Published: August 25, 2026 | Source: https://nanoporetech.com/news/appointment-of-chief-development-and-product-officer-cdpo-and-chief-marketing-and-communications-officer-cmco)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment opportunities in the next-generation sequencing market are expanding across sequencing platforms, consumables, clinical genomics, bioinformatics, artificial intelligence, liquid biopsy, single-cell analysis, and long-read sequencing. Population genomics represents a major infrastructure opportunity because nearly 250,000 whole genomes are already incorporated into one prominent United States research dataset. Investment is also moving toward automated sample preparation, decentralized sequencing, cloud genomic analysis, secure data management, and integrated multiomics.

Pharmaceutical companies require genomic technologies for biomarker discovery and patient stratification, while hospitals need clinically validated sequencing workflows. Emerging markets provide additional opportunities for laboratory infrastructure, genomic databases, technical training, and localized sequencing services.

New Product Development

New product development focuses on higher throughput, improved accuracy, faster processing, workflow automation, long reads, and multiomic capability. Illumina's NovaSeq X development roadmap includes output reaching 35 billion reads and technology targeting Q70 sequencing quality, alongside faster processing and additional flow-cell configurations. New sequencing systems increasingly combine instrument control, library processing, secondary analysis, and cloud connectivity.

Long-read platforms are improving base accuracy and sequencing yield, strengthening applications involving structural variants and complex genomes. Product innovation is also expanding into single-cell sequencing, liquid biopsy, direct RNA analysis, automated oncology panels, and artificial intelligence-assisted variant interpretation, broadening next generation sequencing applications.

Recent Developments

• February 2026 – Illumina – NovaSeq X roadmap expands sequencing output, accuracy, speed, and flexibility. Illumina announced enhancements targeting 35 billion reads, Q70 quality, faster workflows, flexible batching, and expanded multiomic sequencing capabilities across NovaSeq X systems.

• September 2026 – Thermo Fisher Scientific – Oncomine Dx Express receives expanded companion diagnostic indication. Thermo Fisher's sequencing-based test gained an expanded indication detecting ERBB2/HER2 activating mutations to support targeted treatment selection for eligible lung cancer patients.

• August 2026 – Illumina – TruSight Oncology Comprehensive receives expanded RET companion diagnostic indication. The targeted NGS assay expanded clinical use for detecting RET alterations and supporting treatment selection in thyroid and medullary thyroid cancer patients.

• January 2025 – Illumina – NovaSeq X software update improves sequencing quality and laboratory usability. Illumina introduced software version 1.3 with improved flow-cell yield, sample demultiplexing, low-diversity accuracy, secondary analysis, conversion speed, and laboratory integration capabilities.

• July 2025 – Thermo Fisher Scientific – Oncomine Dx Express receives regulatory approval for integrated oncology sequencing. The targeted NGS test detects alterations across DNA and RNA biomarkers using the automated Genexus Dx Integrated Sequencer workflow.

Next Generation Sequencing Market Report Coverage

The next generation sequencing market report covers technology development, application demand, regional performance, competitive positioning, investment activity, product innovation, and clinical adoption. Technology analysis includes ion semiconductor sequencing, sequencing by synthesis, nanopore sequencing, and single-molecule real-time sequencing. SBS represents approximately 62% of the defined technology segmentation, reflecting its established position in high-throughput genomics.

Application coverage includes biotechnology and pharmaceutical companies, research centres, hospitals and clinics, and other specialized users. Regional analysis distributes global participation across 5 geographic groups totaling 100%. The report additionally evaluates precision medicine, population genomics, oncology sequencing, bioinformatics, automation, long-read technologies, multiomics, regulatory developments, and competitive strategies.